| Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients L Derosa, B Routy, M Fidelle, V Iebba, L Alla, E Pasolli, N Segata, ... European urology 78 (2), 195-206, 2020 | 227 | 2020 |
| Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C A Desnoyer, D Pospai, MP Lê, A Gervais, A Heurgué-Berlot, A Laradi, ... Journal of hepatology 65 (1), 40-47, 2016 | 219 | 2016 |
| Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C A Desnoyer, D Pospai, MP Lê, A Gervais, A Heurgué-Berlot, A Laradi, ... Journal of hepatology 65 (1), 40-47, 2016 | 205 | 2016 |
| Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy R Ferrara, M Naigeon, E Auclin, B Duchemann, L Cassard, JM Jouniaux, ... Clinical Cancer Research 27 (2), 492-503, 2021 | 90 | 2021 |
| Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies A Desnoyer, S Broutin, J Delahousse, C Maritaz, L Blondel, O Mir, ... European Journal of Cancer 128, 119-128, 2020 | 56 | 2020 |
| The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers C Freitas, A Desnoyer, F Meuris, F Bachelerie, K Balabanian, V Machelon Cytokine & growth factor reviews 25 (3), 307-316, 2014 | 53 | 2014 |
| Prescriptions médicamenteuses potentiellement inappropriées en gériatrie: quels outils utiliser pour les détecter? A Desnoyer, B Guignard, PO Lang, J Desmeules, N Vogt-Ferrier, ... La Presse Médicale 45 (11), 957-970, 2016 | 52* | 2016 |
| PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients A Desnoyer, AL Blanc, V Pourcher, M Besson, C Fonzo-Christe, ... BMJ open 7 (7), e016070, 2017 | 46 | 2017 |
| DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia A Bignon, A Régent, L Klipfel, A Desnoyer, P de la Grange, V Martinez, ... Blood 125 (16), 2507-2518, 2015 | 45 | 2015 |
| Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T … A Paci, A Desnoyer, J Delahousse, L Blondel, C Maritaz, N Chaput, O Mir, ... European Journal of Cancer 128, 107-118, 2020 | 40 | 2020 |
| Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy JB Pain, MP Lê, M Caseris, C Amiel, L Lassel, C Charpentier, A Desnoyer, ... Antimicrobial agents and chemotherapy 59 (6), 3660-3662, 2015 | 37 | 2015 |
| Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer B Duchemann, J Remon, M Naigeon, L Mezquita, R Ferrara, L Cassard, ... Cancers 12 (12), 3625, 2020 | 32 | 2020 |
| Phase II trial of lenalidomide in HIV-infected patients with previously treated Kaposi's sarcoma: results of the ANRS 154 Lenakap Trial V Pourcher, A Desnoyer, L Assoumou, C Lebbe, A Curjol, AG Marcelin, ... AIDS research and human retroviruses 33 (1), 1-10, 2017 | 31 | 2017 |
| CD8+ PD-1+ to CD4+ PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L) 1 blockers B Duchemann, M Naigeon, E Auclin, R Ferrara, L Cassard, JM Jouniaux, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 23 | 2022 |
| Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer B Duchemann, J Remon, M Naigeon, L Cassard, JM Jouniaux, L Boselli, ... Translational Lung Cancer Research 10 (6), 2937, 2021 | 21 | 2021 |
| Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated … L Carril-Ajuria, A Desnoyer, M Meylan, C Dalban, M Naigeon, L Cassard, ... Journal for Immunotherapy of Cancer 10 (5), 2022 | 17 | 2022 |
| Prevention of potentially inappropriate medication in internal medicine patients: A prospective study using the electronic application PIM‐Check AL Blanc, B Guignard, A Desnoyer, O Grosgurin, C Marti, C Samer, ... Journal of clinical pharmacy and therapeutics 43 (6), 860-866, 2018 | 17 | 2018 |
| Expression pattern of the CXCL 12/CXCR 4–CXCR 7 trio in Kaposi sarcoma skin lesions A Desnoyer, N Dupin, L Assoumou, A Carlotti, F Gaudin, C Deback, ... British Journal of Dermatology 175 (6), 1251-1262, 2016 | 16 | 2016 |
| Deleterious pharmacokinetic interaction between bexarotene and efavirenz A Desnoyer, F Al Kaied, D Descamps, P Yeni, V Descamps, C Le Beller, ... Aids 24 (14), 2296-2298, 2010 | 10 | 2010 |
| Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new? O Mir, S Broutin, A Desnoyer, J Delahousse, N Chaput, A Paci European Journal of Cancer 128, 103-106, 2020 | 8 | 2020 |
jules desmeulesDivision of Clinical Pharmacology and Toxicology, Multidisciplinary Pain Center, Departement ofVerified email at hcuge.ch
